THAP9 and familial pancreatic carcinoma: As shown in Figure 4a,d, pancreatic cancer patients had the highest alteration frequencies in both THAP9 and THAP9-AS1 (>6%), with “amplification” (i.e., more copies, often focal) being the primary alteration type.